Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Featured trial
  • 308 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

  • 816 views
  • 08 Nov, 2020
  • 1 location
Splenic Stimulation for RA

biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). A sufficient number of participants will be enrolled so that approximately 28 participants will undergo device

tumor necrosis factor
baricitinib
DMARD
  • 8 views
  • 31 Oct, 2021
  • 4 locations
The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis

rheumatic drugs are ineffective in the treatment of RA. The addition of tofacitinib to patients may be beneficial to the treatment.

stiffness
synovitis
DMARD
antirheumatics
tofacitinib
  • 8 views
  • 22 Jun, 2021
  • 1 location
Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis (TOLERANT)

anti-rheumatic drugs (DMARD) will be included. Any combination and dose of DMARD is allowed, with exception of Janus kinase inhibitors. Concomitant use of a low dose of prednisone (7.5 mg per day or

remission
DMARD
prednisone
glucocorticoids
antirheumatics
  • 0 views
  • 10 Mar, 2022
  • 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (ADVISE)

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter …

azathioprine
panuveitis
adalimumab
tacrolimus
antimetabolites
  • 140 views
  • 14 Jul, 2022
  • 19 locations
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.

adalimumab
infliximab
golimumab
rheumatoid factor
rheumatism
  • 0 views
  • 22 Apr, 2022
  • 9 locations
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

plaque psoriasis
arthritis
skin lesion
high sensitivity
psoriasis
  • 10 views
  • 14 Oct, 2022
  • 92 locations
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and …

plaque psoriasis
arthritis
skin lesion
high sensitivity
psoriasis
  • 1 views
  • 11 Oct, 2022
  • 107 locations
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial (SPEED)

severe PsA. Arm 1 will receive standard step up therapy in the cohort and act as the control group. Arm 2 will receive early combination conventional synthetic disease modifying anti-rheumatic drugs

sulfasalazine
arthritis
rheumatic diseases
adalimumab
tumor necrosis factor
  • 2 views
  • 02 Jun, 2022
  • 1 location